Therapeutic Vaccine Designed To Reduce Recurrence Of Cervical Cancer Under Study - Latest News

Therapeutic vaccine designed to reduce recurrence of cervical cancer under study

Dr. Sharad A. Ghamande, chief of the Section of Gynecologic Oncology at the Medical College of Georgia and associate director for clinical research at the Georgia Cancer Center at Augusta University. ... read more

Advaxis: First Cancer Vaccine For Cervical Cancer To Be In Pivotal Trial

Advaxis (NASDAQ:ADXS) is a development stage biotechnology company focused on the research, development and commercialization of safe and effective therapeutic cancer vaccines ... recurrent cervical c... read more

Evidence-Based Therapy for Recurrent Cervical Cancer

The patient experienced a complete clinical and radiographic response to therapy ... use biopsy to detect recurrence when possible. The first goal in treating recurrent cervical cancer is adequate sym... read more

The Latest Cancer Research News to Cheer About

Now a trial is studying whether women with ER-positive cancer can safely stop anti-estrogen therapy ... a potential vaccine that would use a woman’s immune system to prevent a recurrence of ovarian ca... read more

How Good Health Became a Numbers Game

Over the same period, the longitudinal Framingham Heart Study (initiated ... of Gardasil on cervical cancer is unknown. As a result, the therapy was marketed not as a vaccine for cancer, but as an exp... read more

Inovio and ApolloBio to Collaborate on Development and Commercialization of HPV Pre-cancer Immunotherapy VGX-3100 in Greater China

VGX-3100 is the world’s first therapeutic vaccine being developed for ... that targets the underlying cause of cervical dysplasia, providing an opportunity for women to reduce their risk of cervical c... read more

Empowering a Change

The department is also working on a few drug therapies, including PARP inhibitors, a new class of oral drugs being designed as a safer, effective, less toxic option for women who’ve had ovarian cancer ... read more

Compelling Phase II Data De-Risks Advaxis

ADXS initiated the Phase II study in November 2010 in India in 110 Patients with recurrent or refractory cervical ... by Advaxis' cancer vaccines has been the most comprehensive and robust so far in t... read more

Cancer of the Uterine Cervix

Pap-smear screening is designed to detect ... Management of Recurrent Disease Approximately 30 percent of women with invasive cervical cancer die from recurrent or persistent disease after the initial ... read more

International Journal of Gynecological Cancer:

Objective: Cervical ... radiation under the umbrella of the GCIG Cervix Cancer Research Network; fourth, adding to the advances in antiangiogenesis therapy in the setting of metastatic disease; and fi... read more

Human Papillomaviruses As Therapeutic Targets in Human Cancer

1 Recurrent ... vaccines have no therapeutic effects and it will take decades before their use will markedly reduce the prevalence of HPV-associated cancers. 98 In contrast, HPV-specific therapeutic v... read more